| 2020 |
Ferrari S, Lewiecki EM, Butler PW, Kendler DL, Napoli N, Huang S, Crittenden DB, Pannacciulli N, Siris E, Binkley N. Favorable skeletal benefit/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed. Bone. May 2020;134:115287. |
1 |
1 |
| 2020 |
Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, McDermott M, Chines A, Huang S, Cummings SR. A pooled analysis of fall incidence from placebo‐controlled trials of denosumab. J Bone Miner Res. June 2020;35(6):1014-1021. |
1 |
1 |
| 2022 |
Farlay D, Rizzo S, Dempster DW, Huang S, Chines A, Brown JP, Boivin G. Bone mineral and organic properties in postmenopausal women treated with denosumab for up to 10 years. J Bone Miner Res. May 2022;37(5):856-864. |
1 |
1 |
| 2022 |
Geusens P, Bevers MSAM, van Rietbergen B, Messina OD, Lespessailles E, Oliveri B, Chapurlat R, Engelke K, Chines A, Huang S, Saag KG, van den Bergh JP. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. June 2022;37(6):1136-1146. |
0 |
0 |
| 2022 |
Cosman F, Huang S, McDermott M, Cummings SR. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res. November 2022;37(11):2112-2120. |
2 |
2 |